# AOD-9604 Before and After: What the Research Shows

> AOD-9604 before and after data from six controlled trials: a Phase IIa 2.6 kg signal at 12 weeks, a failed Phase IIb primary endpoint at 24 weeks, and the cartilage study findings.

The six-trial outcome record — the Phase IIa weight-loss signal, the Phase IIb endpoint result, and the cartilage data — reviewed honestly.

## AOD-9604 Weight Loss Outcomes in Animal and Human Studies

AOD-9604 before and after data splits clearly across species. In rodent models, the evidence is consistent: chronic treatment reduced body-weight gain and adipose-tissue mass, increased in-vivo fat oxidation (measured as elevated plasma glycerol), and reduced cumulative weight gain compared with obese untreated controls [2][5]. The mechanism — beta-3 adrenergic receptor upregulation and acetyl-CoA carboxylase inhibition — was confirmed to be the driver of the chronic effect in knockout experiments [6].

In human studies, the picture is different. The Phase IIa 12-week trial (approximately 300 obese adults, oral administration) produced a 2.6 kg weight loss at the 1 mg/day dose versus 0.8 kg in the placebo group [8]. That is a measurable difference — but it did not survive the rigorous 24-week Phase IIb test. In 536 obese adults over 24 weeks, no dose studied (0.25, 0.5, or 1 mg/day) achieved statistically significant weight reduction versus placebo [9].

This divergence — consistent rodent efficacy, failed human primary endpoint — defines the AOD-9604 record. The compound's lipolytic mechanism operates in humans (it does not do nothing); whether it operates with sufficient magnitude, at available oral doses, to produce a clinically or statistically meaningful body-mass reduction in a properly powered 24-week trial is the question the Phase IIb data answered: at the doses and duration studied, it did not.

## Does AOD-9604 really work?

In animal studies: yes — fat reduction was demonstrated consistently across multiple obese-rodent models with measurable effect sizes [2][5][6]. In humans: the Phase IIa 12-week signal (2.6 kg vs 0.8 kg placebo) was real but not reproduced in the larger, longer Phase IIb trial [8][9]. The Phase IIb OPTIONS study, powered and designed specifically to answer this question in humans, found no statistically significant weight loss versus placebo at 24 weeks [9]. Development was halted on that basis. The compound 'works' in the mechanistic sense — it engages its intended pathways, it does not cause harm, and it does not elevate IGF-1. It did not work to the degree required for pharmaceutical obesity drug approval.

## Evidence summary: does AOD-9604 work?

Strong in-vitro and rodent evidence supports the lipolytic mechanism of AOD-9604 at the cellular and whole-organism level [1][2][3][4][5][6]. The mechanism was well characterized before Phase I human trials began. The clinical evidence from the METAOD program (six trials, approximately 900 subjects) established an exceptional safety record and a Phase IIa efficacy signal [8][10]. The Phase IIb pivotal trial failed its primary endpoint [9]. These are the three pillars of the record — all three are true simultaneously.

For researchers, the compound's interest lies in its selective lipolysis-without-IGF-1 property, its clean human tolerability at up to 1 mg/day over 24 weeks, and the emerging intra-articular osteoarthritis program (NCT07225829). For the obesity indication, the clinical development record is closed.

## Results timeline in studied subjects

Human trial data measured outcomes at 12 weeks (Phase IIa) and 24 weeks (Phase IIb OPTIONS). The 12-week Phase IIa measurement produced the 2.6 kg versus 0.8 kg placebo difference at 1 mg/day [8]. The 24-week Phase IIb measurement at equivalent and lower doses produced no statistically significant difference [9]. Intermediate time points (e.g., 4, 8, 16, or 20 weeks) were not reported in the published summaries reviewed.

Rodent data showed progressive fat-mass reduction and elevated fat-oxidation markers over multi-week chronic treatment periods, consistent with a mechanism that requires sustained receptor upregulation [5][6]. The gap between rodent progressive efficacy and the human Phase IIb null result at 24 weeks has not been resolved in the published literature.

## AOD-9604 Reviews: What Study Participants Reported

Participant-reported experience in the METAOD trials was captured through adverse event monitoring rather than qualitative outcome surveys. Across six trials and approximately 900 participants, the most commonly reported adverse event was mild-to-moderate headache — occurring at similar frequencies in both the treatment and placebo arms, indicating it was not treatment-related [10].

No treatment-related serious adverse events were reported. No participants withdrew from any trial due to AOD-9604 treatment. No participants developed anti-AOD-9604 antibodies. No changes in insulin sensitivity, glucose tolerance, or IGF-1 levels were observed across any participant [10]. In other words: AOD-9604 did not make participants measurably worse on any monitored health parameter.

This is the complete AOD-9604 reviews record sourced from published clinical data. Anecdotal or community-forum reports are outside the scope of this literature digest and are not cited here.

## What weight outcomes were observed in AOD-9604 studies?

Human clinical trials produced two data points. Phase IIa at 12 weeks: 2.6 kg versus 0.8 kg placebo at 1 mg/day oral [8]. Phase IIb at 24 weeks: no statistically significant weight loss versus placebo at 0.25, 0.5, or 1 mg/day oral [9]. Rodent models: meaningful reductions in body fat and cumulative body-weight gain at various systemic doses across ob/ob mice, C57BL/6J lean controls, and Zucker obese rats [2][5][7]. The rodent effect sizes were described as significant within each study's analysis; specific percentage changes were not extracted from the published primary papers reviewed.

## How long does it take to see results from AOD-9604?

The published human trial record measured outcomes at 12 and 24 weeks only. Intermediate time points were not reported in the data reviewed. The 12-week Phase IIa measurement produced a 2.6 kg difference at 1 mg/day [8]; that difference did not persist or expand to statistical significance at 24 weeks in the larger Phase IIb trial [9]. No validated human timeline for onset or peak effect has been established from controlled data.

---

The AOD-9604 record, reduced to essentials — six human trials catalogued, primary endpoint outcome stated, no clinic and no prescription on the premises.